BACKGROUND: 5-Lipoxygenase products play a part in inflammatory response. AIMS: The effect of intracolonic administration of zileuton (a 5-lipoxygenase inhibitor) on colonic damage and eicosanoid local release was assessed in a rat model of colitis. METHODS: Ninety rats with trinitrobenzenesulphonic acid induced colitis were randomised to receive placebo, 5-aminosalicylic acid (50 mg/kg), or zileuton (50 mg/kg) intracolonically for four weeks. Local eicosanoid release was monitored by intracolonic dialysis throughout the study. The colon was removed for macroscopic and histological assessment at weeks 1, 2, and 4 after colitis induction in 10 rats of each group. RESULTS: Zileuton significantly reduced macroscopic damage score after four weeks of treatment in comparison with the other two groups (p = 0.034). In addition, zileuton administration significantly increased the intracolonic release of both thromboxane B2 at week 1 (p = 0.05) and prostaglandin E2 at weeks 2 and 4 (p < 0.05). Zileuton and 5-aminosalicylic acid decreased leukotriene B4 release by 90% at day 3. CONCLUSIONS: Intracolonic zileuton, compared with 5-aminosalicylic acid and placebo, seems to improve the course of the disease in a model of chronic colitis. This effect may be related to an increased and maintained production of prostaglandin E2 together with inhibition of leukotriene B4 synthesis.
BACKGROUND:5-Lipoxygenase products play a part in inflammatory response. AIMS: The effect of intracolonic administration of zileuton (a 5-lipoxygenase inhibitor) on colonic damage and eicosanoid local release was assessed in a rat model of colitis. METHODS: Ninety rats with trinitrobenzenesulphonic acid induced colitis were randomised to receive placebo, 5-aminosalicylic acid (50 mg/kg), or zileuton (50 mg/kg) intracolonically for four weeks. Local eicosanoid release was monitored by intracolonic dialysis throughout the study. The colon was removed for macroscopic and histological assessment at weeks 1, 2, and 4 after colitis induction in 10 rats of each group. RESULTS:Zileuton significantly reduced macroscopic damage score after four weeks of treatment in comparison with the other two groups (p = 0.034). In addition, zileuton administration significantly increased the intracolonic release of both thromboxane B2 at week 1 (p = 0.05) and prostaglandin E2 at weeks 2 and 4 (p < 0.05). Zileuton and 5-aminosalicylic acid decreased leukotriene B4 release by 90% at day 3. CONCLUSIONS: Intracolonic zileuton, compared with 5-aminosalicylic acid and placebo, seems to improve the course of the disease in a model of chronic colitis. This effect may be related to an increased and maintained production of prostaglandin E2 together with inhibition of leukotriene B4 synthesis.
Authors: R Bartolí; F Fernández-Bañares; E Navarro; E Castellà; J Mañé; M Alvarez; C Pastor; E Cabré; M A Gassull Journal: Gut Date: 2000-02 Impact factor: 23.059
Authors: B J R Whittle; C Varga; A Berko; K Horvath; A Posa; J P Riley; K A Lundeen; A M Fourie; P J Dunford Journal: Br J Pharmacol Date: 2007-12-24 Impact factor: 8.739
Authors: Elias Gounaris; Michael J Heiferman; Jeffrey R Heiferman; Manisha Shrivastav; Dominic Vitello; Nichole R Blatner; Lawrence M Knab; Joseph D Phillips; Eric C Cheon; Paul J Grippo; Khashayarsha Khazaie; Hidayatullah G Munshi; David J Bentrem Journal: PLoS One Date: 2015-03-06 Impact factor: 3.240
Authors: S D Dumusc; E C Ontsouka; M Schnyder; S Hartnack; C Albrecht; R M Bruckmaier; I A Burgener Journal: J Vet Intern Med Date: 2014-09-30 Impact factor: 3.333
Authors: Teresa Vezza; Alba Rodríguez-Nogales; Francesca Algieri; Maria Pilar Utrilla; Maria Elena Rodriguez-Cabezas; Julio Galvez Journal: Nutrients Date: 2016-04-09 Impact factor: 5.717
Authors: Sandeep B Subramanya; Sanjana Chandran; Saeeda Almarzooqi; Vishnu Raj; Aisha Salem Al Zahmi; Radeya Ahmed Al Katheeri; Samira Ali Al Zadjali; Peter D Collin; Thomas E Adrian Journal: Mar Drugs Date: 2018-04-30 Impact factor: 5.118